Techstars Announces Two New Executive Team Leaders: Rupa Athreya Appointed Chief Accelerator Investments Officer & Marie Moussavou Appointed Chief Portfolio Services Officer
6.1.2022 16:00:00 EET | Business Wire | Press release
Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, has created two new leadership roles as the company continues to scale to serve more founders around the world. With $850 million in assets under management, 47 accelerator programs in 17 countries, and a global alumni base of more than 2,700 companies, both roles will provide strategic and operational support to thousands of entrepreneurs. Athreya and Moussavou will report directly to the company’s CEO, Maelle Gavet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005289/en/
Newly appointed Chief Accelerator Investments Officer Rupa Athreya (Photo: Business Wire)
“Techstars has an unprecedented ability to impact entrepreneurs through our unique pre-seed investment model that identifies exceptional entrepreneurs worldwide and supports them operationally and financially as they build their businesses,” stated Gavet. “We count on globally experienced executives with the ability to think big-picture, enabling the organization to operate at scale which is why both Marie and Rupa are such wonderful additions to our global management team.”
As the company’s first Chief Accelerator Investments Officer, Rupa Athreya will lead a worldwide team of more than 75 investment professionals who represent Techstars in 37 cities around the world. Techstars operates under the principle that the best founders can come from anywhere, running programs locally in the cities where the entrepreneurs operate or seek to grow. Techstars maintains a small class size ranging from 10 to 12 portfolio companies and runs multiple programs in cities with larger entrepreneur ecosystems. Techstars’ Accelerator Investment Team invested approximately $94 million last year and will continue to grow its portfolio as investors around the world seek to invest in viable early-stage companies. Overseeing this decentralized approach requires a seasoned executive with a strategic mindset, strong operational skills and global experience.
Having worked at global firms such as OppenheimerFunds, JPMorgan Chase, Bloomberg and McKinsey, Athreya has most recently been an independent consultant advising startups and new businesses as well as global financial institutions on strategy, innovation, and go-to-market execution. She has close to 20 years of expertise in building and launching new businesses and products, having led product development at OppenheimerFunds, founded a robo-advisor at Bloomberg and launched the Chase Private Client business at JPMorgan Chase. She has a Ph.D. in Economics from Yale University, a B.A. in Philosophy, Politics and Economics from Oxford University and a B.A. in Economics from the University of Delhi. She will continue to be based out of New York, NY.
As Techstars’ first Chief Portfolio Services Officer, Marie Moussavou will be responsible for advancing growth, providing infrastructure support and investment opportunities for Techstars’ more than 6,500 alumni founders as they lead their companies through later stages. Portfolio Services provides capital and funding, business development and talent connections, mentorship, and knowledge exchange for Techstars’ network of founders, investors, mentors and innovation partners. With this ever-growing network, the Portfolio Services team under Moussavou’s leadership will maintain deep, personal relationships with founders while leveraging robust data management skills to offer founders customized and scalable support.
Moussavou has a proven track record of scaling high growth, customer-focused organizations through innovation and operational excellence. Most recently she worked at Amazon for 15 years in various senior roles, including Technical Advisor to the SVP for International, Director of Alexa Europe, and Director of Operations for Amazon Transportation Services Europe. Marie has an MBA from the London Business School and lives in London, U.K., where she will continue to be based.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,800 companies with a combined market cap of more than $195B. www.techstars.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005289/en/
Contact information
Ali Whitman
ali.whitman@techstars.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 22:11:00 EEST | Press release
Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to further extend its category leadership among legal-age consumers of nicotine products. Like the flagship FDA-authorized ZYN pouches, ZYNULTRA, with its higher moisture content, is fre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
